BOSTON SCIENTIFIC CORP (1BSX.MI) Stock Fundamental Analysis

BIT:1BSX • US1011371077

64.4 EUR
0 (0%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Overall 1BSX gets a fundamental rating of 5 out of 10. We evaluated 1BSX against 65 industry peers in the Health Care Equipment & Supplies industry. 1BSX has an average financial health and profitability rating. 1BSX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • 1BSX had positive earnings in the past year.
  • In the past year 1BSX had a positive cash flow from operations.
  • 1BSX had positive earnings in 4 of the past 5 years.
  • 1BSX had a positive operating cash flow in 4 of the past 5 years.
1BSX.MI Yearly Net Income VS EBIT VS OCF VS FCF1BSX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • 1BSX has a Return On Assets of 6.54%. This is in the better half of the industry: 1BSX outperforms 73.85% of its industry peers.
  • The Return On Equity of 1BSX (11.93%) is better than 72.31% of its industry peers.
  • 1BSX has a better Return On Invested Capital (8.09%) than 67.69% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1BSX is below the industry average of 9.73%.
  • The last Return On Invested Capital (8.09%) for 1BSX is above the 3 year average (6.59%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROIC 8.09%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
1BSX.MI Yearly ROA, ROE, ROIC1BSX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

  • 1BSX's Profit Margin of 14.42% is amongst the best of the industry. 1BSX outperforms 84.62% of its industry peers.
  • 1BSX's Profit Margin has declined in the last couple of years.
  • The Operating Margin of 1BSX (19.40%) is better than 80.00% of its industry peers.
  • In the last couple of years the Operating Margin of 1BSX has remained more or less at the same level.
  • 1BSX has a better Gross Margin (68.57%) than 75.38% of its industry peers.
  • In the last couple of years the Gross Margin of 1BSX has remained more or less at the same level.
Industry RankSector Rank
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
1BSX.MI Yearly Profit, Operating, Gross Margins1BSX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • 1BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for 1BSX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1BSX.MI Yearly Shares Outstanding1BSX.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B
1BSX.MI Yearly Total Debt VS Total Assets1BSX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • 1BSX has an Altman-Z score of 4.48. This indicates that 1BSX is financially healthy and has little risk of bankruptcy at the moment.
  • 1BSX has a better Altman-Z score (4.48) than 76.92% of its industry peers.
  • 1BSX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as 1BSX would need 3.03 years to pay back of all of its debts.
  • 1BSX's Debt to FCF ratio of 3.03 is fine compared to the rest of the industry. 1BSX outperforms 72.31% of its industry peers.
  • A Debt/Equity ratio of 0.48 indicates that 1BSX is not too dependend on debt financing.
  • 1BSX's Debt to Equity ratio of 0.48 is in line compared to the rest of the industry. 1BSX outperforms 47.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Altman-Z 4.48
ROIC/WACC0.84
WACC9.64%
1BSX.MI Yearly LT Debt VS Equity VS FCF1BSX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

  • 1BSX has a Current Ratio of 1.51. This is a normal value and indicates that 1BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • 1BSX has a Current ratio of 1.51. This is comparable to the rest of the industry: 1BSX outperforms 44.62% of its industry peers.
  • 1BSX has a Quick Ratio of 1.51. This is a bad value and indicates that 1BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of 1BSX (0.96) is worse than 63.08% of its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 0.96
1BSX.MI Yearly Current Assets VS Current Liabilites1BSX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.51% over the past year.
  • Measured over the past years, 1BSX shows a very strong growth in Earnings Per Share. The EPS has been growing by 26.01% on average per year.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.9%

3.2 Future

  • 1BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.63% yearly.
  • The Revenue is expected to grow by 10.66% on average over the next years. This is quite good.
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.63%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.66%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1BSX.MI Yearly Revenue VS Estimates1BSX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B
1BSX.MI Yearly EPS VS Estimates1BSX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 24.96, 1BSX is valued on the expensive side.
  • 61.54% of the companies in the same industry are more expensive than 1BSX, based on the Price/Earnings ratio.
  • 1BSX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.10, which is the current average of the S&P500 Index.
  • 1BSX is valuated rather expensively with a Price/Forward Earnings ratio of 21.72.
  • 1BSX's Price/Forward Earnings ratio is in line with the industry average.
  • When comparing the Price/Forward Earnings ratio of 1BSX to the average of the S&P500 Index (28.06), we can say 1BSX is valued slightly cheaper.
Industry RankSector Rank
PE 24.96
Fwd PE 21.72
1BSX.MI Price Earnings VS Forward Price Earnings1BSX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 1BSX's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 1BSX is more expensive than 63.08% of the companies in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as 1BSX.
Industry RankSector Rank
P/FCF 29.5
EV/EBITDA 24.12
1BSX.MI Per share data1BSX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of 1BSX may justify a higher PE ratio.
  • A more expensive valuation may be justified as 1BSX's earnings are expected to grow with 13.68% in the coming years.
PEG (NY)1.68
PEG (5Y)0.96
EPS Next 2Y14.13%
EPS Next 3Y13.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • 1BSX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BOSTON SCIENTIFIC CORP

BIT:1BSX (2/27/2026, 7:00:00 PM)

64.4

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-21
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap95.47B
Revenue(TTM)N/A
Net Income(TTM)2.79B
Analysts85.5
Price Target107.92 (67.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-0.59%
PT rev (3m)-2.57%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0.02%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1%
Valuation
Industry RankSector Rank
PE 24.96
Fwd PE 21.72
P/S 5.83
P/FCF 29.5
P/OCF 24.39
P/B 4.82
P/tB N/A
EV/EBITDA 24.12
EPS(TTM)2.58
EY4.01%
EPS(NY)2.96
Fwd EY4.6%
FCF(TTM)2.18
FCFY3.39%
OCF(TTM)2.64
OCFY4.1%
SpS11.05
BVpS13.36
TBVpS-1.13
PEG (NY)1.68
PEG (5Y)0.96
Graham Number27.85
Profitability
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROCE 10.04%
ROIC 8.09%
ROICexc 8.38%
ROICexgc 28.19%
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
FCFM 19.76%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Debt/EBITDA 2.18
Cap/Depr 59.36%
Cap/Sales 4.14%
Interest Coverage 250
Cash Conversion 90.6%
Profit Quality 136.98%
Current Ratio 1.51
Quick Ratio 0.96
Altman-Z 4.48
F-Score6
WACC9.64%
ROIC/WACC0.84
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.9%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.66%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.52%
EBIT Next 3Y20.65%
EBIT Next 5Y17.42%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%

BOSTON SCIENTIFIC CORP / 1BSX.MI FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 1BSX.MI.


What is the valuation status for 1BSX stock?

ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (1BSX.MI). This can be considered as Overvalued.


What is the profitability of 1BSX stock?

BOSTON SCIENTIFIC CORP (1BSX.MI) has a profitability rating of 6 / 10.


What are the PE and PB ratios of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (1BSX.MI) is 24.96 and the Price/Book (PB) ratio is 4.82.


What is the expected EPS growth for BOSTON SCIENTIFIC CORP (1BSX.MI) stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (1BSX.MI) is expected to grow by 14.83% in the next year.